Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.52 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 14/20 | 0.41 |
| ▸ | CA2 | P00918 | 14/20 | 0.41 |
| ▸ | MMP9 | P14780 | 3/20 | 0.40 |
| ▸ | MMP13 | P45452 | 3/20 | 0.40 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 5/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9491700 | 0.77 | CHRM1 (0.46) | CA1CA2MMP9CA7CA14 | |
| SCHEMBL1287927 | 0.77 | CHRM1 (0.41) | HDAC7HDAC8HDAC6HDAC9HDAC5 | |
| SCHEMBL6340106 | 0.71 | CA1 (0.53) | HDAC7HDAC8HDAC6HDAC9HDAC5 | |
| SCHEMBL247697 | 0.70 | — | — | |
| SCHEMBL30117075 | 0.70 | — | — | |
| Valpropylhydroxamic Acid SCHEMBL15310210 | 0.69 | HDAC8 (1.00) | HDAC7HDAC8HDAC6HDAC9HDAC5 | |
| SCHEMBL17976934 | 0.68 | HDAC8 (0.41) | HDAC7HDAC8HDAC6HDAC9HDAC5 | |
| SCHEMBL28705417 | 0.68 | MMP9 (0.55) | HDAC7HDAC8HDAC6HDAC9HDAC5 | |
| SCHEMBL28935319 | 0.68 | MMP9 (0.55) | HDAC7HDAC8HDAC6HDAC9HDAC5 | |
| SCHEMBL28694225 | 0.68 | MMP9 (0.55) | HDAC7HDAC8HDAC6HDAC9HDAC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488754-B2 | Method for the treatment of polycystic kidney disease | WYETH (US) | 2009-02-10 | — | — | US | disclosed |
| US-7485667-B2 | Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors | WYETH HOLDINGS CORPORATION (US) | 2009-02-03 | — | — | US | disclosed |
| US-7282496-B2 | Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and TACE inhibitors | WYETH HOLDINGS CORPORATION (US) | 2007-10-16 | — | — | US | disclosed |
| US-20070155834-A1 | Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors | WYETH HOLDINGS CORPORATION (US) | 2007-07-05 | — | — | US | disclosed |
| US-7199155-B2 | Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors | WYETH HOLDINGS CORPORATION (US) | 2007-04-03 | — | — | US | disclosed |
| US-6946473-B2 | Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors | WYETH HOLDINGS CORPORATION (US) | 2005-09-20 | — | — | US | disclosed |
| US-20050113346-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | WYETH HOLDINGS CORPORATION | 2005-05-26 | — | — | US | disclosed |
| WO-2005021489-A2 | ACETYLENIC ARYL SULFONATE HYDROXAMIC ACID TACE AND MATRIX METALLOPROTEINASE INHIBITORS | WYETH HOLDINGS CORPORATION (US) | 2005-03-10 | — | — | WO | disclosed |
| US-6812227-B2 | SULFUR COMPOUNDS SUCH AS 2-((4-BUT-2-YNYLOXY-BENZENESULFONYL)-METHYL-AMINO)-N-HYDROXY-3-METHYL -BUTYRAMIDE, USED AS TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME (TACE) INHIBITORS, FOR PROPHYLAXIS OF RHEUMATIC DISEASES, SEPSIS OR INFLAMMATION | WYETH HOLDINGS CORPORATION | 2004-11-02 | — | — | US | disclosed |
| EP-1149074-B1 | ACETYLENIC SULFONAMIDE THIOL TACE INHIBITORS | WYETH CORP (US) | 2004-10-20 | — | — | EP | disclosed |
| EP-1144369-A2 | ACETYLENIC ARYL SULFONAMIDE AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS | American Cyanamid Company (US) | 2001-10-17 | — | — | EP | disclosed |
| US-6277885-B1 | INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME | AMERICAN CYANAMID COMPANY | 2001-08-21 | — | — | US | disclosed |
| US-6225311-B1 | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors | AMERICAN CYANAMID COMPANY | 2001-05-01 | — | — | US | disclosed |
| US-6200996-B1 | ARTHRITIS; BONE, GASTROINTESTINAL DISORDERS; CROHN*S DISEASE, MULTIPLE SCLEROSIS | AMERICAN CYANAMID COMPANY | 2001-03-13 | — | — | US | disclosed |
| WO-2000044709-A2 | ACETYLENIC α-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
| WO-2000044716-A1 | ACETYLENIC SULFONAMIDE THIOL TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
| WO-2000044749-A1 | ACETYLENIC ORTHO-SULFONAMIDO AND PHOSPHINIC ACID AMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
| WO-2000044711-A1 | ACETYLENIC $G(b)-SULFONAMIDO AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
| WO-2000044710-A2 | ACETYLENIC ARYL SULFONAMIDE AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
| WO-2000044740-A2 | HETEROARYL ACETYLENIC SULFONAMIDE AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155834-A1 | Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors | TNF, SI, TNFRSF1A | HDAC7 26/4885HDAC8 160/4885HDAC6 90/4885 |
| US-20050113346-A1 | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors | TNF, SI, MMP12 | HDAC7 80/4885HDAC8 452/4885HDAC6 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.